﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Academy of Medical Sciences of I.R. Iran</PublisherName>
      <JournalTitle>Archives of Iranian Medicine</JournalTitle>
      <Issn>1029-2977</Issn>
      <Volume>21</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2018</Year>
        <Month>09</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Retrospective Analysis of 345 Multiple Myeloma Cases: An Investigation from 2 Institutions</ArticleTitle>
    <FirstPage>412</FirstPage>
    <LastPage>417</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hasan</FirstName>
        <LastName>Jalaeikhoo</LastName>
      </Author>
      <Author>
        <FirstName>Morteza</FirstName>
        <LastName>Sharifzadeh</LastName>
      </Author>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Rajaeinejad</LastName>
      </Author>
      <Author>
        <FirstName>Manoutchehr</FirstName>
        <LastName>Keyhani</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Zokaasadi</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>13</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>06</Month>
        <Day>03</Day>
      </PubDate>
    </History>
    <Abstract>Background: Multiple myeloma (MM) accounts for a substantial mortality rate among hematological cancers. The prognosis of the disease has been noticeably changed during the past 2 decades. This study reports a retrospective analysis of 345 MM cases from 2 cancer centers. Methods: Medical records of 345 MM cases were analyzed in retrospect. Diagnosis of MM was defined in presence of at least 10% plasma cells in bone marrow biopsy and one of the CRAB findings (hypercalcemia, renal failure, anemia and myeloma bone lesions). Survival analysis was performed using Kaplan-Meier method, and the effects of prognostic variables were assessed by Cox proportional hazards model. Results: The mean age of the patients was 61.98 ± 11.44 years. Comparing to Mayo Clinic series, our patients were relatively younger and suffered from more advanced disease. By a median follow up time of 45 months, 1- and 5-year overall survival (OS) rates were 78.0% and 35.6%, respectively. Regarding first progression free survival (PFS1), similar rates of 57.7% and 17.0% were observed respectively. In multivariate analysis, hypercalcemia (corrected serum calcium &gt;11 mg/dL), pancytopenia and elevated serum creatinine (Cr) (&gt;2 mg/dL) were found to be independent prognostic factors affecting OS. Conclusion: Presentation of MM in Iran which is a developing country, was significantly different from developed countries. This finding might be generalized to other developing countries as well. In addition, vincristine-adriamycin-dexamethasone (VAD) therapy was an inferior protocol compared to bortezomib as first and second lines. Furthermore, pancytopenia was observed in about 9% of the patients and was an independent prognosticator of the disease. </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bortezomib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multiple myeloma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancytopenia</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>